Fertility startup Gameto has received permission from the FDA to see if its ovary-in-a-dish technology can make in vitro ...
The Trump administration said on Wednesday it will consider “opportunities to bring greater transparency” to the ...
Zentalis Pharmaceuticals is axing about 40% of its staff and doubling down on advancing its only pipeline candidate as part ...
A Delaware judge issued a split ruling in a bizarre legal squabble over the IPO plans of Aurion Biotech, which should allow ...
The first of two confirmation hearings is now underway for Robert F. Kennedy, Jr. to serve as President Donald Trump’s HHS ...
Embattled genetics testing giant 23andMe is thinking of selling itself as it runs out of cash. The company needs ...
Curie.Bio reveals $340M seed fund, Cullinan's zipalertinib succeeds in lung cancer trial, Benchling cuts 10% staff, I-Mab reduces workforce, Regulus shares Phase 1b data, Imvax raises $29M ...
Novo Nordisk is asking a federal appeals court to make haste on its case challenging the Inflation Reduction Act's drug ...
Lonza said Wednesday morning it is on the hunt for deals to increase its capacity and technology offerings, which comes after ...
Affini-T Therapeutics appears to have cut staff last week, according to LinkedIn posts from people who say they are or were ...
President Donald Trump’s communications and travel freeze at HHS may be part of the reason an upcoming FDA advisory committee ...
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is now approved to treat a new subset of breast cancer patients with very low levels of HER2 protein.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback